pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 37 Non-oncology: 21
Oncology: 16
Under Consideration for Negotiation 25 Non-oncology: 18
Oncology: 7
Completed Negotiations 426 With Letter of Intent: 367
Without agreement: 59
Negotiations That Were Not Pursued 83

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Forxiga AstraZeneca Canada Inc. Heart failure, NYHA class II or III
Abevmy BGP Pharma ULC Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma
Bambevi Apotex Inc. Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma
Riabni Amgen Canada Inc. Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Osnuvo AVIR Pharma Inc. osteoporosis

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Kalydeco Vertex Pharmaceuticals (Canada) Incorporated cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Orkambi Vertex Pharmaceuticals (Canada) Incorporated Cystic Fibrosis, F508del CFTR mutation
Noromby Juno Pharmaceuticals Corp. Deep vein thrombosis (treatment and prevention)
Blincyto Amgen Canada Inc. Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Odomzo Sun Pharma Canada Inc. Basal Cell Carcinoma (BCC): For the treatment of adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery
Pomalyst Celgene Inc. Multiple Myeloma (Relapsed)